ACD/Labs is a leading provider of scientific software solutions that facilitate effective decision making and digital transformation in chemical and pharmaceutical R&D. We enable organizations to leverage harmonized analytical, structural, and molecular information—for use by chemists and data scientists alike—in a FAIR-compliant environment. Our science-centric solutions, supported by cloud-enabled technologies, automate, manage, and proliferate chemically intelligent knowledge. For decades, ACD/Labs has helped leading R&D organizations through digitalization and engineering of data for AI initiatives. As part of Revvity Signals we will continue to help create efficiencies in workflows that improve productivity and accelerate scientific innovation.

Pion supports the development of lifesaving and life-enhancing drugs by providing tools for drug developers, formulations scientists, and pharmaceutical production. For early-stage drug developers, our cutting-edge analytical technologies and services enable in vitro measurements of solubility, permeability, pKa and lipophilicity, providing essential data to improve candidate selection and formulations decisions for both oral and subcutaneous dosage forms. Later in development, high-pressure homogenizers enable particle size reduction and ensure material consistency from bench- to production-scale.

Seda Pharmaceutical Development Services specialises in integrated Pharmaceutical Development and Clinical Pharmacology. Our mission is to facilitate the efficient development of optimal medicinal products, ranging from conventional to complex formulations, by leveraging scientific excellence. We are experts in all facets of dose selection and justification, including Drug Metabolism and Pharmacokinetics (DMPK), Clinical Pharmacology, Pharmaceutical Development, IND-NDA technical authoring, and GMP manufacturing. Our comprehensive suite of services encompasses consultancy, laboratory analysis, pharmacokinetic modelling and GMP manufacturing. This expertise enables us to guide clients through the entire drug development process, from initial discovery and preclinical studies to clinical trials and regulatory approval. Our focus is on designing and developing products that exhibit superior in vivo performance, robust manufacturability, and strong commercial potential. Based in Greater Manchester, UK, our cutting-edge facilities are equipped to support the rapid design, development, evaluation, and production of innovative formulations. By enhancing the value proposition of our global clients, we contribute to the advancement of new therapies, ultimately benefiting patients worldwide.

Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development studies.  Selvita was established in 2007 and currently employs almost 900 professionals, of which over 40% hold a PhD degree. The Company research sites are located in Krakow (HQ) and Wroclaw, Poland, as well as Zagreb, Croatia. Selvita’s international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK. Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS. The company offers drug discovery support at every stage of the early discovery phase up to the preclinical development. Selvita specializes in a variety of drug discovery processes from in silico drug design and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro and in vivo pharmacology, structural biology, all tailored to the customer’s needs.